NORCROSS, GA--(Marketwired - Dec 17, 2013) - RayBiotech, Inc. ("RBI") today announced that it has entered into a partnership with the Genomics Core Facility of Fox Chase Cancer Center. Under the terms of the partnership, RayBiotech will provide comprehensive GLP-compliant biomarker discovery and validation services to Fox Chase Cancer Center and its researchers. In addition, RayBiotech will offer GMP-compliant and ISO 13485: 2003-certified diagnostic discovery products to the Genomics Core Facility and Fox Chase Cancer Center researchers campus-wide. These services and products correspond to RayBiotech's broad range of antibody array and ELISA product lines and will be provided under preferred pricing conditions specifically formulated for Fox Chase Cancer Center.
Dr. Yuesheng Li, Director of the Fox Chase Cancer Center Genomics Core, said, "For a number of years we have been intrigued with RayBiotech's biomarker discovery and characterization technologies. We are pleased to now have RayBiotech as a formal partner in our pursuit of biomarkers to more accurately define cancer."
Commenting on the partnership, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, "Fox Chase Cancer Center has been at the forefront of cancer research for decades. Part of the Center's progress in understanding and diagnosing the underpinnings of cancer is the result of cancer-related biomarker discovery initiatives. RayBiotech's antibody array and ELISA technologies perfectly complement the pursuit and characterization of cancer-related diagnostics markers by Fox Chase researchers. We here at RayBiotech are proud to now be formally associated with this endeavor and look forward to providing the Fox Chase Cancer Center Genomics Core and all Fox Chase researchers with preferred access to our proprietary biomarker discovery technologies."
About RayBiotech, Inc.
In 2001 RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485: 2003 certification and are featured in thousands of publications, including: Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).